Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, 730050, China.
Gansu Provincial Academic Institute for Medical Research, Lanzhou, 730050, China.
Endocrine. 2021 Sep;73(3):617-624. doi: 10.1007/s12020-021-02690-5. Epub 2021 Mar 23.
Thyroid-stimulating hormone (TSH) is a growth factor affecting the initiation or progression of papillary thyroid cancer (PTC). However, the relationship between preoperative serum TSH and papillary thyroid microcarcinoma (PTMC) remains controversial. To investigate the relationship between preoperative serum TSH and tumor status of PTMC, a multicentered retrospective study was performed from January 2014 to December 2016. The cohort of this study consisted of 1997 patients who underwent thyroid surgery. Serum TSH concentrations were measured and PTMC was diagnosed based on the post-operation pathological report. Results showed that the preoperative serum TSH concentration was not related to age and gender but was positively associated with tumor size. Furthermore, higher TSH level was associated with extra-thyroidal extension and lymph node metastasis (LNM). These results indicated that TSH might not be involved in the development of PTMC but may be associated with PTMC progression. Preoperative serum TSH concentration should be considered as risk predictor for tumor progression in patients with PTMC.
促甲状腺激素（TSH）是一种生长因子，影响甲状腺乳头状癌（PTC）的发生或进展。然而，术前血清 TSH 与甲状腺微小乳头状癌（PTMC）之间的关系仍存在争议。为了研究术前血清 TSH 与 PTMC 肿瘤状态之间的关系，本研究于 2014 年 1 月至 2016 年 12 月进行了一项多中心回顾性研究。本研究队列由 1997 名接受甲状腺手术的患者组成。测量了血清 TSH 浓度，并根据术后病理报告诊断为 PTMC。结果表明，术前血清 TSH 浓度与年龄和性别无关，但与肿瘤大小呈正相关。此外，较高的 TSH 水平与甲状腺外侵犯和淋巴结转移（LNM）有关。这些结果表明，TSH 可能不参与 PTMC 的发生，但可能与 PTMC 的进展有关。术前血清 TSH 浓度应被视为 PTMC 患者肿瘤进展的风险预测因子。
